Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Aug 20;7:121–131. doi: 10.2147/JIR.S67751

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Manetta et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Tabalumab neutralizes soluble or membrane-bound human BAFF co-stimulation of B-cells.

Notes: (A) Primary human CD19⁺ B-cells were co-stimulated with 25 ng/mL soluble BAFF plus anti-IgM/IL-4 in the presence of a dose response of tabalumab or isotype control. Proliferation was measured using ³H-thymidine incorporation at day 5. (B) Primary human CD19⁺ B-cells were co-stimulated with 2.3 ng/mL soluble BAFF or 5.5 ng/mL membrane-bound BAFF plus anti-IgM/IL-4. Gray bars represent cells treated with 1 μg/mL tabalumab, black bars represent cells treated with 1 μg/mL isotype control. Stimulation with anti-IgM/IL-4 alone produced a relatively low proliferative signal of 3640 ± 592 CPM. Proliferation was measured using ³H-thymidine incorporation at day 3. Data are presented as mean ± SD.

Abbreviations: BAFF, B-cell activating factor; CPM, counts per minute; Ig, immunoglobulin; IL, interleukin; mem, membrane-bound; SD, standard deviation.